Inavolisib (GDC-0077) is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).
Moores Cancer Center at UC San Diego Health, La Jolla, California, United States
California Cancer Associates for Research & Excellence, Inc., San Marcos, California, United States
Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States
Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Ellison Institute of Technology, Los Angeles, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.